NovoMix® 50 and 70
:Type 1 and 2 diabetes
:Filed for registration
NovoMix® 50: Launched in Europe, approved in the US and Japan
NovoMix® 70: Launched in Europe and approved in Japan
The aim is to develop and market other premixed formulations of the rapid acting insulin analogue - insulin aspart - as part of a biphasic insulin aspart product range. NovoMix® 50 and NovoMix® 70 will be linked to the introduction of a three times daily concept in type 1 and type 2 diabetes for superior glycaemic control without increasing theriskof hypoglycaemia, hence NovoMix® 50 and NovoMix® 70 are targeted towards more intensified premix therapy.
- Company announcements
- Novo Nordisk insulin analogues have proven safety profiles (28 Jun 2009)
- Novo Nordisk refocuses its activities within inhaled insulin and discontinues the development of AERx® (14 Jan 2008)
- Novo Nordisk announces major expansion of its diabetes care field force in the US (30 Nov 2006)
- Read more company announcements
- Press releases
- The 4-T study of intensified insulin regimens shows excellent three-year glucose control with low risk of hypoglycaemia in type 2 diabetes (22 Oct 2009)
- New data shows that type 2 diabetes patients who start insulin therapy with once-daily NovoMix® 30 achieve significantly greater HbA1c reduction than with insulin glargine. 1 (02 Oct 2009)
- New study directly comparing insulin delivery devices shows that Next Generation FlexPen® has a significantly lower injection force than SoloStar® and KwikPen® (29 May 2009)
- Read more press releases
- Scientific abstracts
- Advances in Therapy (2008)
- American Journal of Physiology-Endocrinology and Metabolism (2004)
- Biochemistry (2005)
- Read more scientific abstracts
